Affinage

TEFM

Transcription elongation factor, mitochondrial · UniProt Q96QE5

Length
360 aa
Mass
41.7 kDa
Annotated
2026-06-10
11 papers in source corpus 9 papers cited in narrative 8 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 5/5 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

TEFM is the mitochondrial transcription elongation factor that converts the mitochondrial RNA polymerase POLRMT from a distributive into a highly processive enzyme capable of producing genome-length transcripts (PMID:21278163, PMID:25690892). It binds directly and RNase-resistantly to the catalytic region of POLRMT, and within mitochondria forms an RNA-dependent complex with nascent mitochondrial transcripts and processing factors including PTCD3 and DHX30; TEFM forms foci coincident with sites of newly synthesized mitochondrial RNA (PMID:21278163). In a fully reconstituted system, TEFM increases POLRMT affinity for elongation-like DNA:RNA templates, suppresses pausing, and abolishes premature termination at conserved sequence block II (CSB II) (PMID:25690892); single-molecule measurements localize this effect to a reduction in the frequency and duration of long-lived pauses and an increase in POLRMT stall force, with no change in the intrinsic elongation rate (PMID:30514634). Beyond elongation, TEFM couples transcription to mtDNA maintenance: its loss collapses promoter-distal transcript synthesis, causes accumulation of unprocessed transcripts and recruitment of additional RNA processing factors, and impairs de novo mtDNA replication (PMID:31036713), while in human cells TEFM facilitates the RNA-to-DNA transition at the H-strand replication origin (OH), supporting 7S DNA formation, strand-asynchronous replication, and mtDNA copy number (PMID:39922921). Pathogenic TEFM variants in patients reduce promoter-distal mitochondrial transcripts in muscle and fibroblasts, and tefm loss in zebrafish produces neuromuscular and mitochondrial defects, establishing TEFM loss of function as disease-causing (PMID:36823193).

Mechanistic history

Synthesis pass · year-by-year structured walk · 7 steps
  1. 2011 High

    Established that human mitochondria require a dedicated elongation factor by identifying TEFM as a POLRMT-binding partner essential for synthesis of promoter-distal transcripts.

    Evidence RNAi knockdown with respiratory readout, mitochondrial affinity purification/Co-IP with RNase controls, deletion mapping, in vitro processivity assay, and live-cell imaging of RNA foci

    PMID:21278163

    Open questions at the time
    • Did not define the precise pausing/termination sites suppressed by TEFM
    • Functional roles of co-purifying PTCD3 and DHX30 left unresolved
  2. 2015 High

    Demonstrated with purified components that TEFM alone is sufficient to confer processivity, suppress pausing, and block termination at CSB II, directly linking it to the replication-primer decision point.

    Evidence Fully reconstituted in vitro transcription system with recombinant TEFM; transcript-length, termination, and template-binding affinity assays

    PMID:25690892

    Open questions at the time
    • Did not resolve the physical mechanism by which pauses are suppressed
    • In vitro CSB II behavior not yet connected to in vivo replication switching
  3. 2018 High

    Resolved the kinetic mechanism of TEFM action, showing it acts on pause dynamics and mechanical stability rather than the catalytic elongation rate.

    Evidence Single-molecule optical-tweezers transcription assay tracking pause frequency, pause duration, and stall force

    PMID:30514634

    Open questions at the time
    • Structural basis of pause suppression not determined from kinetics alone
    • Single-lab measurement
  4. 2019 High

    Showed in vivo that TEFM is essential for development and couples elongation to both RNA processing and mtDNA replication, broadening its role beyond processivity.

    Evidence Conditional Tefm knockout mouse hearts, deep RNA sequencing, BioID proximity labeling, and mtDNA replication quantification

    PMID:31036713

    Open questions at the time
    • Identities and direct roles of BioID-detected processing factors not validated
    • Mechanism linking elongation defect to replication failure not resolved at molecular level
  5. 2023 Medium

    Connected TEFM loss of function to human disease, confirming the in vivo requirement for TEFM in producing promoter-distal transcripts.

    Evidence Patient muscle and fibroblast RNA analysis plus zebrafish tefm morpholino knockdown with neuromuscular and mitochondrial readouts

    PMID:36823193

    Open questions at the time
    • Mechanistic detail limited to transcript-level evidence
    • Variant-specific biochemical consequences not characterized
  6. 2025 Medium

    Defined a distinct role for TEFM in promoting the RNA-to-DNA transition at OH, positioning it as a balancer of transcription versus replication.

    Evidence Human TEFM knockout cells with quantification of 7S DNA, replication intermediates, mtDNA copy number, and promoter-proximal tRNA levels

    PMID:39922921

    Open questions at the time
    • Not independently replicated
    • Molecular mechanism of the RNA-to-DNA handoff at OH not resolved
  7. 2025 Medium

    Provided structural snapshots of how TEFM is recruited as the mitochondrial transcription machinery transitions from initiation to processive elongation.

    Evidence Cryo-EM structures of transcription complex intermediates capturing TFAM/TFB2M release and TEFM recruitment (preprint)

    PMID:bio_10.1101_2025.04.03.647028

    Open questions at the time
    • Preprint not yet peer-reviewed
    • No TEFM-specific functional validation accompanying the structures

Open questions

Synthesis pass · forward-looking unresolved questions
  • How TEFM-dependent processivity, RNA processing regulation, and the OH RNA-to-DNA switch are mechanistically coordinated within a single elongation complex remains unresolved.
  • No unified molecular model linking pause suppression to replication-primer handoff
  • Direct roles of TEFM-associated RNA processing factors uncharacterized

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0003723 RNA binding 2 GO:0098772 molecular function regulator activity 2 GO:0140110 transcription regulator activity 2
Localization
GO:0005739 mitochondrion 2
Pathway
R-HSA-74160 Gene expression (Transcription) 2 R-HSA-69306 DNA Replication 1 R-HSA-8953854 Metabolism of RNA 1
Partners
DHX30POLRMTPTCD3TFAMTFB2M
Complex memberships
mitochondrial transcription elongation complex

Evidence

Reading pass · 8 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2011 TEFM is required for mitochondrial transcription elongation in human cells; RNAi knockdown causes respiratory incompetence and loss of promoter-distal mitochondrial transcripts from both H- and L-strands. Affinity purification from mitochondria shows TEFM forms a complex with POLRMT (mitochondrial RNA polymerase), mitochondrial transcripts, PTCD3, and DHX30; after RNase treatment only POLRMT remains associated with TEFM. TEFM interacts with the catalytic region of POLRMT (defined by deletion mutants). In vitro, TEFM enhances POLRMT processivity on ss- and dsDNA templates. TEFM contains two HhH motifs and an RNase H fold, similar to nuclear elongation factor Spt6. TEFM forms foci coincident with newly synthesized mitochondrial RNA in cultured cells. RNAi knockdown with respiratory phenotype readout; affinity purification/Co-IP from mitochondria; RNase treatment to define RNA-dependent vs. direct interactions; deletion mutagenesis to map POLRMT interaction; in vitro transcription processivity assay; live-cell imaging of foci Nucleic acids research High 21278163
2015 Recombinant TEFM strongly stimulates POLRMT processivity in a fully reconstituted in vitro mitochondrial transcription system, dramatically increasing formation of longer transcripts. TEFM abolishes premature transcription termination at conserved sequence block II (CSB II), a site linked to replication primer formation. TEFM also substantially increases POLRMT affinity for an elongation-like DNA:RNA template. In the absence of TEFM, POLRMT pauses at many sites leading to termination; TEFM suppresses this effect. Reconstituted in vitro transcription system with recombinant TEFM; processivity and transcript-length analysis; template-binding affinity assays Nucleic acids research High 25690892
2018 Single-molecule optical-tweezers assay revealed that TEFM enhances POLRMT transcription elongation by reducing the frequency of long-lived pauses and shortening their durations, without changing the pause-free elongation rate. TEFM also increases the stall force of POLRMT. At CSB II, TEFM modulates how POLRMT passes through this sequence, relevant to the switch between DNA replication and transcription. Single-molecule optical-tweezers transcription assay; real-time tracking of pause dynamics and stall force Biophysical journal High 30514634
2019 Conditional Tefm knockout in mouse hearts is embryonically lethal and causes drastic reduction of promoter-distal mitochondrial transcripts; promoter-proximal transcripts increase but mostly terminate before the replication-transcription switch region, leading to profoundly reduced de novo mtDNA replication. Deep RNA sequencing of Tefm knockout tissue revealed accumulation of unprocessed mitochondrial transcripts, indicating TEFM also regulates mitochondrial RNA processing. BioID proximity-labeling showed TEFM interacts with multiple RNA processing factors in addition to POLRMT. Conditional knockout mouse model; deep RNA sequencing; BioID proximity labeling; mtDNA replication quantification EMBO reports High 31036713
2023 Pathogenic TEFM variants in human patients cause reduced levels of promoter-distal mitochondrial RNA transcripts in muscle and primary fibroblasts, confirming that TEFM enhances POLRMT processivity in vivo. Tefm knockdown in zebrafish embryos produces neuromuscular junction abnormalities and abnormal mitochondrial function, establishing a genotype-phenotype correlation for TEFM loss of function. Patient-derived muscle and fibroblast RNA analysis; zebrafish tefm morpholino knockdown with NMJ and mitochondrial function readouts Nature communications Medium 36823193
2025 TEFM knockout in human cells decreases 7S DNA levels, strand-asynchronous replication intermediates, and mtDNA copy number, indicating that TEFM promotes the RNA-to-DNA transition at the H-strand replication origin (OH). Concurrently, tRNAs encoded near transcription promoters increase in TEFM knockout, indicating enhanced transcription initiation frequency. These data demonstrate that TEFM balances mitochondrial transcription and replication by facilitating transition from RNA synthesis to DNA synthesis at OH, in addition to conferring processivity to POLRMT. TEFM knockout cells; quantification of 7S DNA, replication intermediates, mtDNA copy number, and tRNA levels Communications biology Medium 39922921
2025 Cryo-EM structures capture the mitochondrial transcription complex transitioning from open promoter complex to processive elongation complex through intermediate stages. These structures reveal the sequential disengagement of mtRNAP from TFAM and the promoter, release of TFB2M, and the recruitment of TEFM to the elongation complex, providing structural detail on how TEFM is incorporated into the transcription machinery. Cryo-EM structural determination of transcription complex intermediates bioRxiv (preprint)preprint Medium bio_10.1101_2025.04.03.647028
2021 In hepatocellular carcinoma cells, TEFM overexpression promotes ROS production and subsequent activation of ERK signaling; knockdown reduces these effects. TEFM co-localizes with mitochondria in LUAD cells and its absence disrupts mitochondrial transcripts and respiratory chain complex expression, causes mitochondrial membrane depolarization and elevated ROS leading to apoptosis. TEFM overexpression/knockdown in HCC and LUAD cell lines; ROS measurement; ERK pathway activity assays; JC-1 mitochondrial membrane potential staining; xenograft tumor models Cell death & disease Low 33771980 39075464

Source papers

Stage 0 corpus · 11 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2011 TEFM (c17orf42) is necessary for transcription of human mtDNA. Nucleic acids research 145 21278163
2015 TEFM is a potent stimulator of mitochondrial transcription elongation in vitro. Nucleic acids research 89 25690892
2019 TEFM regulates both transcription elongation and RNA processing in mitochondria. EMBO reports 67 31036713
2023 TEFM variants impair mitochondrial transcription causing childhood-onset neurological disease. Nature communications 25 36823193
2021 Elevated TEFM expression promotes growth and metastasis through activation of ROS/ERK signaling in hepatocellular carcinoma. Cell death & disease 25 33771980
2018 TEFM Enhances Transcription Elongation by Modifying mtRNAP Pausing Dynamics. Biophysical journal 12 30514634
2024 Identification of TEFM as a potential therapeutic target for LUAD treatment. Journal of translational medicine 9 39075464
2024 Mitochondrial transcription elongation factor TEFM promotes malignant progression of gliomas. Cancer cell international 6 39719635
2024 TEFM facilitates uterine corpus endometrial carcinoma progression by activating ROS-NFκB pathway. Journal of translational medicine 2 39731053
2025 TEFM facilitates transition from RNA synthesis to DNA synthesis at H-strand replication origin of mtDNA. Communications biology 0 39922921
2025 Clinical and Radiological Characterization of TEFM-Associated Neurological Disorder. American journal of medical genetics. Part A 0 40272035

Missed literature

Know a paper Affinage missed for TEFM? Flag it for the maintainers and the community.

No submissions yet.